Etiprednol dicloacetate  (Synonyms: BNP 166; Etiprednol dichloroacetate)

Etiprednol dicloacetate (BNP 166) is an anti-inflammatory agent. Etiprednol dicloacetate inhibits eosinophil accumulation. Etiprednol dicloacetate can be used in the research of inflammatory airway diseases, such as asthma^[1][2].

Etiprednol dicloacetate (1 nM-1 μM) inhibits LPS-induced TNF-α production by human blood^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Etiprednol dicloacetate (0-100 μg/kg, intranasal inhalation) attenuates peribronchial eosinophilia in the lung of the allergen sensitized and challenged rats^[1].
Etiprednol dicloacetate (0.1 μg/kg, intranasal inhalation) inhibits eosinophil accumulation in rats (antigen-induced airway eosinophil infiltration)^[3].
Etiprednol dicloacetate (0-20 mg/kg, p.o., 28 days) is well tolerated in rats and dogs^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

485.40

C₂₄H₃₀Cl₂O₆

199331-40-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. István Kurucz, et al. Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166). J Pharmacol Exp Ther. 2003 Oct;307(1):83-92.  [Content Brief]

  [2]. A Miklós, et al. 28-day oral toxicity study with soft corticosteroid BNP-166 in rats and dogs, followed by a 14-day recovery period. Pharmazie. 2002 Feb;57(2):142-6.  [Content Brief]

  [3]. I Kurucz, et al. Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, anti-asthmatic steroid. Pharmazie. 2004 May;59(5):412-6.  [Content Brief]